SVF
Insufficient· Insufficient EvidenceNarrative Review

Joint-on-a-Chip: The Future of Preclinical Modelling of Joint Diseases.

Pye JS., Zhang Y., Lin X., Yousefi M., Wen C., Li JJ.

Narrative Review on Osteoarthritis, Cartilage Damage, Hip Osteoarthritis, Autoimmune Research, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Healthc Mater (2026)
Country
Germany
Reported sample size
—
PMID
41460083
DOI
10.1002/adhm.202504487

Abstract (original English)

Joint diseases, including osteoarthritis (OA) and rheumatoid arthritis (RA), are leading causes of disability worldwide and pose a major socioeconomic burden. Effective treatments remain limited, partly due to difficulties in understanding and replicating complex joint structures as well as the dynamic interactions among multiple tissues and immune components. Traditional in vitro and animal models are restricted in their ability to accurately simulate the human joint microenvironment, limiting their predictive value for drug discovery and therapeutic development. Joint-on-a-Chip (JOC) is emerging as a powerful platform for studying joint diseases, providing a physiologically relevant microenvironment on a microfluidic chip that integrates key joint tissues, such as cartilage, subchondral bone, synovium, and adipose tissue, along with mechanical and biochemical cues. This review provides a comprehensive analysis of current JOC models, highlighting their key features, advantages, and limitations. We discuss advances in model features, chip manufacturing, and microenvironment regulation, including mechanical and biological stimulation that improve JOC fabrication and functionality. We also critically analyse the challenges of JOC designs, including the ability to faithfully mimic joint dynamics, immune interactions, and long-term tissue viability. Finally, we outline future direc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansLab-On-A-Chip DevicesAnimalsJoint DiseasesArthritis, RheumatoidOsteoarthritisJointsModels, Biological
HipOsteoarthritisCartilage DamageHip OsteoarthritisAutoimmune Research
View on PubMedDOI

Related research